Zhengzhou University
Clinical trials sponsored by Zhengzhou University, explained in plain language.
-
New cocktail aims to tackle rare lymphoma without chemo
Disease control Not yet recruitingThis study tests a combination of three drugs—zanubrutinib, rituximab, and lenalidomide—as the first treatment for people with marginal zone lymphoma that has spread or requires therapy. Researchers want to see if this drug mix helps tumors shrink or disappear and how safe it is.…
Phase: NA • Sponsor: Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New combo therapy offers hope for hard-to-treat lymphoma patients
Disease control Not yet recruitingThis study tests a combination of four drugs (zuberitamab, selinexor, dexamethasone, and thalidomide) in 30 adults with mantle cell lymphoma that came back or didn't respond to BTK inhibitors. The goal is to improve remission rates and keep the cancer under control longer. Partic…
Phase: PHASE4 • Sponsor: Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New combo therapy aims to tackle rare brain cancer
Disease control Not yet recruitingThis study tests a new approach for primary central nervous system lymphoma (PCNSL), a rare brain cancer. It combines CAR-T cell therapy, a stem cell transplant, and two drugs (orelabrutinib and sintilimab) to see if the mix is safe and effective. The trial plans to enroll 30 adu…
Phase: NA • Sponsor: Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC